Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
75.06
+0.63 (+0.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HYZN, BMRN and AMRN
October 28, 2021
NEW YORK, NY / ACCESSWIRE / October 28, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies....
From
The Gross Law Firm
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMarin's Q3 Net Income Hit By Lower Product Sales
October 28, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million. The decline...
Via
Benzinga
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZEV, BMRN and AMRN
October 28, 2021
AMRN The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss,...
From
The Klein Law Firm
Via
AccessWire
Topics
Fraud
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
BioMarin Pharmaceutical inc (BMRN) Q3 2021 Earnings Call Transcript
October 28, 2021
BMRN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
BMRN ALERT: Robbins Geller Rudman & Dowd LLP Announces that BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
October 27, 2021
SAN DIEGO, CA / ACCESSWIRE / October 27, 2021 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) securities between...
From
Robbins Geller Rudman & Dowd LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
BIOMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against BioMarin Pharmaceuticals and Encourages Investors to Contact the Firm
October 27, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Lawsuits Filed Against SAM, BMRN and RECAF - Jakubowitz Law Pursues Shareholders Claims
October 27, 2021
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
Biomarin Pharmaceutical: Q3 Earnings Insights
October 27, 2021
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement....
Via
Benzinga
SHAREHOLDER ALERT: INNV HEPS BMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
October 27, 2021
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...
From
The Law Offices of Vincent Wong
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
CLASS ACTION UPDATE for EAR, NNOX and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
October 27, 2021
NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 27, 2021
From
The Schall Law Firm
Via
Business Wire
LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 26, 2021
From
The Schall Law Firm
Via
Business Wire
CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies....
From
Levi & Korsinsky, LLP
Via
AccessWire
Topics
Initial Public Offering
Lawsuit
Exposures
Financial
Legal
Product Safety
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
October 26, 2021
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to...
From
The Klein Law Firm
Via
AccessWire
Topics
Fraud
Intellectual Property
Exposures
Intellectual Property
Legal
Product Safety
SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
October 26, 2021
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...
From
The Law Offices of Vincent Wong
Via
AccessWire
Topics
Fraud
Intellectual Property
Lawsuit
Exposures
Financial
Intellectual Property
Legal
Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims
October 25, 2021
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies...
From
Jakubowitz Law
Via
AccessWire
Topics
Fraud
Lawsuit
Exposures
Financial
Legal
Product Safety
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
October 25, 2021
From
Rosen Law Firm
Via
Business Wire
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
October 16, 2021
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc.
September 22, 2021
San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Exposures
Product Safety
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
September 09, 2021
Stifel
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
September 09, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:
Via
Benzinga
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
September 07, 2021
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 07, 2021
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...
Via
Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
September 07, 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene...
Via
Benzinga
Exposures
Product Safety
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
August 27, 2021
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The...
Via
Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
August 20, 2021
All it will take is an FDA approval and a partial repeat of history.
Via
The Motley Fool
Exposures
Product Safety
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
July 29, 2021
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,...
Via
Talk Markets
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.